Effects of Travoprost on Neovascular Glaucoma

NCT00441181•Federal University of São Paulo

Summary

Prostaglandin analogues have not been used in the treatment of neovascular glaucoma because of suspicious lack of efficacy. This study aims at assessing the effect of travoprost on neovascular glaucoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Neovascular glaucoma of known cause
•Older than 18 years
•Previously submitted to retinal photocoagulation
•Under medical treatment to glaucoma

Exclusion Criteria

•Need of antiglaucomatous surgery
•Previous ocular surgery in the last 6 months
•Pregnancy

Locations (1)

Federal University of São Paulo

São Paulo, São Paulo, Brazil

Key Dates

Start Date

January 1, 2008

Completion Date

December 1, 2008

Last Updated

June 22, 2011

Enrollment

ESTIMATED participants

Conditions

Neovascular Glaucoma

Interventions

Travoprost

DRUG

Clinical Characteristics of Neovascular Glaucoma

NCT07177807

Neovascular Glaucoma

View study

COMPLETEDNA

A Study on the Treatment Strategy of NVG Secondary to PDR

NCT05156021

Neovascular GlaucomaProliferative Diabetic Retinopathy

View study

UNKNOWNPHASE2/PHASE3

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 22, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions